APPROACHES TO SPECIFIC NEOPLASMS: ACQUIRED IMMUNE DEFICIENCY SYNDROME

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

APPROACHES TO SPECIFIC NEOPLASMS: ACQUIRED IMMUNE DEFICIENCY SYNDROME

Comprehensive Textbook of Oncology. Second Edition. Moossa AR et al, eds. Baltimore, Williams and Wilkins, p. 1313-36, 1991.. Unique Identifier : AIDSLINE ICDB/91676558
Anonymous; No affiliation given

Abstract: Since 1981, when the first cases of AIDS were reported by the Centers for Disease Control, much has been learned about this disorder. Dramatic scientific achievements have occurred nearly every year since AIDS was first defined; these include discovery of the etiologic agent (HIV), development of a blood test for antibodies to HIV, and deployment of the first treatment. Advances also were made in the treatment of secondary infections and Kaposi's sarcoma. Approaches to AIDS are reviewed in the following chapters: epidemiology and societal implications of AIDS; etiology and immune dysfunction of AIDS (HIV genome, life cycle of HIV, cytopathic effect of HIV on target cells, host immunologic response to HIV infection, diagnosis of HIV infection, and immunopathogenesis of human HIV infection); clinical implications of AIDS (treatment of HIV, opportunistic infections, neoplastic diseases [Kaposi's sarcoma, non-Hodgkin's lymphoma, and miscellaneous malignancies]); and future directions in the treatment of HIV and AIDS (overview of clinical testing [resources for investigations, conduct of clinical trials, end points and therapy, and special problems], chemotherapeutic agents [azidothymidine, AZT] therapeutic testing, therapeutic options with AZT, alternative antiviral agents, passive immunotherapy, and immunomodulators), and vaccine research.

Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/IMMUNOLOGY/ *THERAPY Antiviral Agents/THERAPEUTIC USE Combined Modality Therapy Forecasting Human HIV-1/IMMUNOLOGY HIV-2/IMMUNOLOGY Opportunistic Infections/THERAPY Risk Factors MONOGRAPH
912130
M91C4073

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .